vs
Side-by-side financial comparison of Insulet Corporation (PODD) and UPBOUND GROUP, INC. (UPBD). Click either name above to swap in a different company.
UPBOUND GROUP, INC. is the larger business by last-quarter revenue ($1.2B vs $761.7M, roughly 1.6× Insulet Corporation). Insulet Corporation runs the higher net margin — 12.0% vs 1.7%, a 10.3% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (33.9% vs 10.9%). Insulet Corporation produced more free cash flow last quarter ($89.5M vs $24.0M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (24.9% CAGR vs 4.5%).
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
Upbound Group, Inc. is a leading US provider of flexible lease-to-own solutions for consumer goods. It offers furniture, consumer electronics, home appliances, and accessories, catering to customers seeking accessible payment alternatives to traditional retail financing.
PODD vs UPBD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $761.7M | $1.2B |
| Net Profit | $91.1M | $19.7M |
| Gross Margin | 69.5% | 49.0% |
| Operating Margin | 16.0% | 4.8% |
| Net Margin | 12.0% | 1.7% |
| Revenue YoY | 33.9% | 10.9% |
| Net Profit YoY | 157.3% | -36.3% |
| EPS (diluted) | $1.30 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $761.7M | — | ||
| Q4 25 | $783.7M | $1.2B | ||
| Q3 25 | $706.3M | $1.2B | ||
| Q2 25 | $649.1M | $1.2B | ||
| Q1 25 | $569.0M | $1.2B | ||
| Q4 24 | $597.5M | $1.1B | ||
| Q3 24 | $543.9M | $1.1B | ||
| Q2 24 | $488.5M | $1.1B |
| Q1 26 | $91.1M | — | ||
| Q4 25 | $101.6M | $19.7M | ||
| Q3 25 | $87.6M | $13.2M | ||
| Q2 25 | $22.5M | $15.5M | ||
| Q1 25 | $35.4M | $24.8M | ||
| Q4 24 | $100.7M | $31.0M | ||
| Q3 24 | $77.5M | $30.9M | ||
| Q2 24 | $188.6M | $33.9M |
| Q1 26 | 69.5% | — | ||
| Q4 25 | 72.6% | 49.0% | ||
| Q3 25 | 72.2% | 48.3% | ||
| Q2 25 | 69.7% | 49.4% | ||
| Q1 25 | 71.9% | 46.8% | ||
| Q4 24 | 72.1% | 47.1% | ||
| Q3 24 | 69.3% | 47.8% | ||
| Q2 24 | 67.7% | 49.4% |
| Q1 26 | 16.0% | — | ||
| Q4 25 | 18.7% | 4.8% | ||
| Q3 25 | 16.7% | 4.5% | ||
| Q2 25 | 18.7% | 4.4% | ||
| Q1 25 | 15.6% | 5.3% | ||
| Q4 24 | 18.3% | 7.3% | ||
| Q3 24 | 16.2% | 6.6% | ||
| Q2 24 | 11.2% | 7.5% |
| Q1 26 | 12.0% | — | ||
| Q4 25 | 13.0% | 1.7% | ||
| Q3 25 | 12.4% | 1.1% | ||
| Q2 25 | 3.5% | 1.3% | ||
| Q1 25 | 6.2% | 2.1% | ||
| Q4 24 | 16.9% | 2.9% | ||
| Q3 24 | 14.2% | 2.9% | ||
| Q2 24 | 38.6% | 3.2% |
| Q1 26 | $1.30 | — | ||
| Q4 25 | $1.42 | $0.35 | ||
| Q3 25 | $1.24 | $0.22 | ||
| Q2 25 | $0.32 | $0.26 | ||
| Q1 25 | $0.50 | $0.42 | ||
| Q4 24 | $1.38 | $0.55 | ||
| Q3 24 | $1.08 | $0.55 | ||
| Q2 24 | $2.59 | $0.61 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $480.4M | $120.5M |
| Total DebtLower is stronger | $18.6M | — |
| Stockholders' EquityBook value | $1.3B | $695.7M |
| Total Assets | $3.0B | $3.3B |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $480.4M | — | ||
| Q4 25 | — | $120.5M | ||
| Q3 25 | — | $107.0M | ||
| Q2 25 | — | $106.8M | ||
| Q1 25 | — | $107.3M | ||
| Q4 24 | — | $60.9M | ||
| Q3 24 | — | $85.1M | ||
| Q2 24 | — | $82.5M |
| Q1 26 | $18.6M | — | ||
| Q4 25 | $930.8M | — | ||
| Q3 25 | $934.9M | — | ||
| Q2 25 | $939.0M | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.5B | $695.7M | ||
| Q3 25 | $1.4B | $687.3M | ||
| Q2 25 | $1.5B | $685.5M | ||
| Q1 25 | $1.3B | $679.2M | ||
| Q4 24 | $1.2B | $629.0M | ||
| Q3 24 | $1.1B | $611.8M | ||
| Q2 24 | $998.4M | $596.3M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.2B | $3.3B | ||
| Q3 25 | $3.0B | $3.2B | ||
| Q2 25 | $3.5B | $3.1B | ||
| Q1 25 | $3.5B | $3.0B | ||
| Q4 24 | $3.1B | $2.6B | ||
| Q3 24 | $3.0B | $2.6B | ||
| Q2 24 | $2.9B | $2.6B |
| Q1 26 | 0.01× | — | ||
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.68× | — | ||
| Q2 25 | 0.64× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.21× | — | ||
| Q2 24 | 1.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $113.8M | $41.6M |
| Free Cash FlowOCF − Capex | $89.5M | $24.0M |
| FCF MarginFCF / Revenue | 11.8% | 2.0% |
| Capex IntensityCapex / Revenue | 3.2% | 1.5% |
| Cash ConversionOCF / Net Profit | 1.25× | 2.11× |
| TTM Free Cash FlowTrailing 4 quarters | $415.7M | $238.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $113.8M | — | ||
| Q4 25 | $183.3M | $41.6M | ||
| Q3 25 | $125.7M | $118.4M | ||
| Q2 25 | $196.5M | $7.8M | ||
| Q1 25 | $63.8M | $137.7M | ||
| Q4 24 | $147.7M | $-61.9M | ||
| Q3 24 | $98.5M | $106.2M | ||
| Q2 24 | $96.5M | $15.0M |
| Q1 26 | $89.5M | — | ||
| Q4 25 | $48.2M | $24.0M | ||
| Q3 25 | $100.1M | $97.9M | ||
| Q2 25 | $177.9M | $-10.4M | ||
| Q1 25 | $51.5M | $127.2M | ||
| Q4 24 | $94.1M | $-74.0M | ||
| Q3 24 | $71.8M | $88.3M | ||
| Q2 24 | $74.0M | $613.0K |
| Q1 26 | 11.8% | — | ||
| Q4 25 | 6.2% | 2.0% | ||
| Q3 25 | 14.2% | 8.4% | ||
| Q2 25 | 27.4% | -0.9% | ||
| Q1 25 | 9.1% | 10.8% | ||
| Q4 24 | 15.7% | -6.9% | ||
| Q3 24 | 13.2% | 8.3% | ||
| Q2 24 | 15.1% | 0.1% |
| Q1 26 | 3.2% | — | ||
| Q4 25 | 17.2% | 1.5% | ||
| Q3 25 | 3.6% | 1.8% | ||
| Q2 25 | 2.9% | 1.6% | ||
| Q1 25 | 2.2% | 0.9% | ||
| Q4 24 | 9.0% | 1.1% | ||
| Q3 24 | 4.9% | 1.7% | ||
| Q2 24 | 4.6% | 1.3% |
| Q1 26 | 1.25× | — | ||
| Q4 25 | 1.80× | 2.11× | ||
| Q3 25 | 1.43× | 8.96× | ||
| Q2 25 | 8.73× | 0.50× | ||
| Q1 25 | 1.80× | 5.56× | ||
| Q4 24 | 1.47× | -2.00× | ||
| Q3 24 | 1.27× | 3.44× | ||
| Q2 24 | 0.51× | 0.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PODD
| Omnipod | $515.6M | 68% |
| International Omnipod | $242.9M | 32% |
| Drug Delivery | $3.3M | 0% |
UPBD
Segment breakdown not available.
